Digital therapeutics: companies, startups and research

Omada Health, Click Therapeutics and Philips are among the organizations active in digital therapeutics. Omada delivers digital programs combining behavior-change support and clinical care for chronic conditions. Click Therapeutics develops prescription digital treatments, including Motivista for negative symptoms of schizophrenia. Company activity spans therapeutic software, clinical development and commercialization, so a strong fit depends on the condition and care model under consideration.

The listed startups include Better Therapeutics, Everex and Hyfe. Better Therapeutics develops prescription software using cognitive behavioral therapy for cardiometabolic conditions; Everex focuses on app-based musculoskeletal rehabilitation. Hyfe uses phone-based acoustic cough detection to support behavioral cough suppression therapy and partnered with Kyorin on a prescription treatment for chronic cough in Japan. Their different clinical targets make direct comparison difficult.

Harvard University, the University of California and Catholic University of Korea are among the active research organizations. Harvard work spans areas such as pelvic health, mental health and cancer care. University of California researchers evaluate online interventions for alcohol misuse and weight management, while Catholic University of Korea studies rehabilitation and panic disorder interventions. Their activity covers both clinical applications and evaluation.

The recorded totals are $72.9 million across 52 grants since 2020 and $2.64 billion across 38 funding rounds. These are broad aggregate figures, not a verified total for a defined set of digital therapeutics companies or products. Funding entries can vary in relevance, so assess individual awards and rounds before using the totals to benchmark a company or investment opportunity.

Click Therapeutics, Inc. leads the listed patent holders with 29 patents. Remedy Health is listed with 8, followed by WELT Corporation with 5 and Welt Corp with 4. The holders indicate where recorded patent ownership is concentrated, but counts alone do not show patent quality, remaining term, claim scope or whether a patent applies to a particular product or market.

No: patent activity declined 28.9% in the last 12 months compared with the previous 12 months, with 77 patents recorded in the 24-month window. Publication activity moved in the opposite direction, rising 36.4% to 1,871 publications last year. This divergence suggests research output is expanding faster than patenting, though it does not establish how many findings will become products.

Recent developments include SAFE_DTx, a safety-first framework for AI-driven personalization published in September 2026, and a study challenging the assumption that greater usage time produces better therapeutic outcomes. A pilot study examined ACESO-APP, a personalized exercise app with real-time feedback for infants with congenital muscular torticollis. In October 2026, Click Therapeutics’ Motivista received FDA clearance for negative symptoms of schizophrenia.

The listed applications include mental health, substance use disorders, chronic pain and musculoskeletal conditions, diabetes and metabolic conditions, neurodevelopmental and cognitive conditions, and vision disorders. Research examples include digital treatment for schizophrenia symptoms, exercise support for infant torticollis and game-based training for children with ADHD. These applications differ in therapeutic goals and evidence needs, so product evaluation should be indication-specific.

The main approaches are behavioral therapy programs, cognitive training, therapeutic games, biofeedback and sensor-guided therapy, and immersive therapy. Behavioral programs structure behavior change, while cognitive training and games use interactive exercises. Sensor-guided approaches adapt feedback to measurements, and immersive therapy places users in virtual experiences. Each has different implementation needs; all require evidence that the intervention improves clinical outcomes.